Nuance market cap is $17 b, and annual revenue was $1.48 b in FY 2020

Nuance Gross profit (Q2, 2021)220.3 M

Nuance Gross profit margin (Q2, 2021), %63.5%

Nuance Net income (Q2, 2021)-3.6 M

Nuance EBIT (Q2, 2021)39.9 M

Nuance Cash, 31-Mar-2021342.9 M

Nuance EV18.3 B

Nuance revenue was $1.48 b in FY, 2020 which is a 18.9% year over year decrease from the previous period.

Nuance revenue breakdown by business segment: 61.9% from Healthcare, 35.8% from Enterprise and 2.3% from Other

Nuance revenue breakdown by geographic segment: 80.2% from United States and 19.8% from International

USD | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|

## Revenue | 2.1b | 1.8b | 1.5b |

| 6% | (11%) | (19%) |

## Cost of goods sold | 873.6m | 779.9m | 638.9m |

## Gross profit | 1.2b | 1.0b | 840.0m |

| 57% | 57% | 57% |

## Sales and marketing expense | 388.3m | 303.5m | 273.3m |

## R&D expense | 305.3m | 275.9m | 226.2m |

## General and administrative expense | 229.8m | 175.0m | 156.4m |

## Operating expense total | 1.3b | 910.5m | 727.4m |

## Depreciation and amortization | 91.1m | 103.6m | 157.4m |

## EBIT | (86.9m) | 132.7m | 112.6m |

| (4%) | 7% | 8% |

## Interest expense | 137.3m | 120.1m | 94.0m |

## Interest income | 9.3m | 13.7m | 4.5m |

## Pre tax profit | (216.7m) | 25.7m | 10.0m |

## Income tax expense | (56.8m) | (88.6m) | (18.8m) |

## Net Income | (159.9m) | 213.8m | 21.4m |

## EPS | (0.5) | 0.7 | 0.1 |

USD | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|

## Cash | 592.3m | 316.0m | 561.0m |

## Accounts Receivable | 395.4m | 378.8m | 308.6m |

## Current Assets | 1.3b | 928.6m | 1.3b |

## PP&E | 176.5m | 155.9m | 141.3m |

## Goodwill | 3.6b | 3.5b | 3.2b |

## Total Assets | 5.9b | 5.3b | 5.4b |

## Accounts Payable | 94.6m | 84.5m | 104.9m |

## Short-term debt | 376.1m | 1.1b | |

## Current Liabilities | 1.1b | 764.2m | 1.8b |

## Long-term debt | 2.2b | 2.2b | 793.5m |

## Total Debt | 2.6b | 2.2b | 1.9b |

## Total Liabilities | 4.0b | 3.6b | 3.2b |

## Common Stock | 294.0k | 291.0k | 290.0k |

## Additional Paid-in Capital | 2.6b | 2.6b | 2.6b |

## Retained Earnings | (580.0m) | (740.8m) | (293.6m) |

## Total Equity | 1.9b | 1.7b | 2.2b |

## Debt to Equity Ratio | 1.4 x | 1.3 x | 0.9 x |

## Debt to Assets Ratio | 0.4 x | 0.4 x | 0.4 x |

## Financial Leverage | 3.1 x | 3.1 x | 2.5 x |

USD | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|

## Net Income | 213.8m | ||

## Depreciation and Amortization | 234.4m | 210.3m | 158.8m |

## Accounts Receivable | (6.3m) | 19.6m | 1.1m |

## Accounts Payable | (1.2m) | (14.3m) | 22.9m |

## Cash From Operating Activities | 378.9m | 444.4m | 401.4m |

## Capital Expenditures | (61.8m) | (48.8m) | (44.2m) |

## Cash From Investing Activities | (334.2m) | (37.3m) | 296.0m |

## Long-term Borrowings | (634.6m) | (482.4m) | (300.0m) |

## Cash From Financing Activities | 67.1m | (680.3m) | (452.0m) |

## Net Change in Cash | 110.7m | (276.3m) | 245.0m |

## Free Cash Flow | 317.0m | 395.6m | 357.2m |

USD | FY, 2017 |
---|---|

## Debt/Equity | 1.4 x |

## Debt/Assets | 0.4 x |

## Financial Leverage | 3.1 x |

FY, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | FY, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | FY, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | FY, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | FY, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | FY, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|

## New Bookings | $2.4 b | $303.8 m | $304.7 m | $484.4 m | $1.5 b | $308.7 m | $313.7 m | $362.9 m | $1.5 b | $380.3 m | $410.4 m | $438.5 m | $1.7 b | $418.4 m | $376.6 m | $471.1 m | $1.7 b | |||||||

## Patents Issued | 3.3 k | 3.6 k | 3.65 k | 4.5 k | 4.07 k | 3.55 k | ||||||||||||||||||

## Patent Applications | 1 k | 1 k | 900 | 800 | 575 | 450 | ||||||||||||||||||

## Countries | 65 | 77 | 79 | 81 | 85 | |||||||||||||||||||

## Remaining Performance Obligations | $2 b | $2 b | $2.01 b | $2.1 b | $1.72 b | $1.73 b | $1.75 b |

- Source: SEC Filings